News | August 07, 2014

Tryton Enrolls First Patient in the EXTENDED Access Registry

A single arm study designed to support FDA submission for U.S. approval

Tryton Side Branch Stent EXTENDED Access Registry

August 7, 2014 — Tryton Medical Inc. announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm clinical study of its Tryton Side Branch Stent. The Tryton IDE XA registry is designed to support FDA submission for U.S. approval and is expected to enroll 133 patients from Europe and the United States. Indulis Kumsars, M.D., P. Stradins University Hospital, Latvian Centre of Cardiology enrolled the first patient.

The Tryton IDE XA registry builds on the results of the TRYTON IDE Study, which showed the benefit of the Tryton Side Branch Stent in the intended population, complex bifurcation lesions involving significant (>2.25 mm RVD by QCA) side branches. The Tryton IDE XA Registry is designed to confirm these results in the intended population. Results from this registry together with the results from the Pivotal IDE Trial will be submitted to the U.S. Food and Drug Administration to seek approval of the device in the United States.

Martin Leon, M.D., FACC, professor of medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, and founder and chairman emeritus of the Cardiovascular Research Foundation, serves as principal investigator of the pivotal IDE trial and EXTENDED Access Registry.

"We look forward to the Extended Access Registry to confirm the improved outcomes observed in patients with complex bifurcation lesions involving significant side branches, the intended cohort of the TRYTON IDE Study,” said Leon. "I thank the EXTENDED Access Registry investigators for continuing to contribute to this important work."

“The Tryton Side Branch Stent allows me to treat complex bifurcation lesions in a predictable way securing the large side branch from onset of procedure,” said Kumsars. “I am excited to participate in this study that I expect to confirm the low Tryton peri?procedural MI rates in side branches larger than 2.25 mm, confirming the post?hoc analysis from the pivotal study.”

The Tryton Side Branch Stent is commercially available in Europe and parts of the Middle East, is investigational in the U.S. and is not available in Japan.

Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re?narrowing of the stented vessel following implantation. In patients undergoing PCI?stenting, approximately one?third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

For more information:,

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init